What is William Blair’s Forecast for TENX FY2024 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – William Blair raised their FY2024 earnings per share estimates for shares of Tenax Therapeutics in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now forecasts that the specialty pharmaceutical company will earn ($0.60) per share for the year, up from their previous estimate of ($6.90). William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. William Blair also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.93) EPS and FY2027 earnings at ($1.03) EPS.

A number of other research firms have also recently commented on TENX. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating for the company. Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Leerink Partners initiated coverage on Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price on the stock. Finally, Guggenheim began coverage on Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target for the company. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Tenax Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Tenax Therapeutics Trading Down 1.4 %

TENX stock opened at $4.87 on Monday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $41.92. The firm’s fifty day simple moving average is $3.99 and its two-hundred day simple moving average is $3.69.

Institutional Investors Weigh In On Tenax Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vestal Point Capital LP purchased a new stake in Tenax Therapeutics in the 3rd quarter valued at about $288,000. Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics during the third quarter valued at approximately $173,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Tenax Therapeutics in the third quarter valued at approximately $101,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.